Table 3 Effectiveness of the ChAdOx1-S and BNT162b2 booster vaccines against symptomatic disease following infection with the Omicron variant for adults aged 40 years and older in England

40–64

Unvaccinated

27,361

51,265

Baseline

Baseline

Dose 2^c

n/a

175+

85,175

89,230

0.92 (0.9–0.94)

8 (6–9.9)

Booster

Any^d

0–1

11,879

7715

0.8 (0.77–0.83)

20.3 (17.2–23.3)

Any^d

2–6

27,430

21,422

0.74 (0.72–0.76)

25.8 (23.7–27.8)

BNT162b2

7–13

28,809

17,658

0.42 (0.41–0.43)

58.2 (57.0–59.4)

BNT162b2

14–34

86,719

66,406

0.36 (0.35–0.37)

63.8 (63.0–64.5)

BNT162b2

35–69

87,592

90,787

0.43 (0.42–0.44)

57.3 (56.4–58.2)

BNT162b2

70–104

22,504

29,379

0.54 (0.52–0.55)

46.4 (45.0–47.8)

BNT162b2

105+

2758

4278

0.69 (0.66–0.73)

30.6 (26.8–34.3)

ChAdOx1-S

7–13

70

40

0.39 (0.25–0.59)

61.2 (40.9–74.6)

ChAdOx1-S

14–34

193

159

0.48 (0.38–0.61)

51.7 (38.9–61.8)

ChAdOx1-S

35–69

216

215

0.47 (0.38–0.57)

53.0 (42.6–61.6)

ChAdOx1-S

70–104

69

97

0.59 (0.43–0.81)

40.8 (18.6–56.9)

ChAdOx1-S

105+

10

14

0.63 (0.27–1.44)

37.2 (−44.1 to 72.6)

65+

Unvaccinated

1701

2361

Baseline

Baseline

Dose 2^c

n/a

175+

4466

3053

0.81 (0.73–0.88)

19.5 (11.7–26.6)

Booster

Any^d

0–1

428

110

0.65 (0.5–0.85)

34.6 (14.8–49.8)

Any^d

2–6

1140

370

0.71 (0.61–0.84)

28.6 (16.0–39.3)

BNT162b2

7–13

1883

433

0.42 (0.36–0.48)

58.1 (51.6–63.8)

BNT162b2

14–34

14,311

3010

0.31 (0.29–0.34)

68.5 (65.7–71.2)

BNT162b2

35–69

36,300

25,240

0.46 (0.42–0.49)

54.1 (50.5–57.5)

BNT162b2

70–104

14,210

18,317

0.6 (0.55-0.65)

40.1 (35.2–44.5)

BNT162b2

105+

1970

2789

0.77 (0.7–0.85)

23.1 (15.1–30.5)

ChAdOx1-S

7–13

23

8

0.34 (0.14–0.83)

66.1 (16.6–86.3)

ChAdOx1-S

14–34

53

32

0.48 (0.3–0.79)

51.6 (20.8–70.4)

ChAdOx1-S

35–69

88

81

0.56 (0.4–0.78)

44.5 (22.4–60.2)

ChAdOx1-S

70–104

16

40

1.27 (0.7–2.32)

−27.2 (−131.6 to 30.1)

ChAdOx1-S

105+

3

5

0.98 (0.23–4.28)

N too low